Development of a neural rosette formation assay (RoFA) to identify neurodevelopmental toxicants and to characterize their transcriptome disturbances.

Cell Differentiation / drug effects Gene Expression Regulation / drug effects Humans Neural Stem Cells / cytology Neurodevelopmental Disorders / chemically induced Neurotoxins / pharmacology Oligonucleotide Array Sequence Analysis Rosette Formation / methods Time Factors Toxicity Tests / methods
Cytotoxicity Developmental toxicity Differentiation Gene expression Human stem cells Neural precursor cells Neural rosettes Phenotypic anchoring

Journal

Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615

Informations de publication

Date de publication:
01 2020
Historique:
received: 05 09 2019
accepted: 05 11 2019
pubmed: 13 11 2019
medline: 20 2 2021
entrez: 13 11 2019
Statut: ppublish

Résumé

The first in vitro tests for developmental toxicity made use of rodent cells. Newer teratology tests, e.g. developed during the ESNATS project, use human cells and measure mechanistic endpoints (such as transcriptome changes). However, the toxicological implications of mechanistic parameters are hard to judge, without functional/morphological endpoints. To address this issue, we developed a new version of the human stem cell-based test STOP-tox

Identifiants

DOI: 10.1007/s00204-019-02612-5 PMID: 31712839
pubmed: 31712839
doi: 10.1007/s00204-019-02612-5
pii: 10.1007/s00204-019-02612-5
doi:

Substances chimiques

Neurotoxins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-171

Subventions

Organisme : CSRD VA
ID : 1
Pays : United States
Organisme : Horizon 2020
ID : 681002
Pays : International
Organisme : Horizon 2020
ID : 825759
Pays : International
Organisme : Deutsche Forschungsgemeinschaft
ID : RTG1331
Pays : International
Organisme : Deutsche Forschungsgemeinschaft
ID : KoRS-CB
Pays : International
Organisme : CSRD VA
ID : 1
Pays : United States
Organisme : CSRD VA
ID : 1
Pays : United States

Commentaires et corrections

Type : CommentIn

Auteurs

Nadine Dreser (N)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany.
ORCID: 0000-0002-7103-0990

Katrin Madjar (K)

Department of Statistics, TU Dortmund, 44221, Dortmund, Germany.

Anna-Katharina Holzer (AK)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany.

Marion Kapitza (M)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany.

Christopher Scholz (C)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany.

Petra Kranaster (P)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany.
Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, 78457, Konstanz, Germany.

Simon Gutbier (S)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany.
Roche Pharma Development, Grenzacherstrasse, 4070, Basel, Switzerland.

Stefanie Klima (S)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany.

David Kolb (D)

Department of Computer and Information Science, University of Konstanz, 78457, Konstanz, Germany.
KNIME GmbH, 78467, Konstanz, Germany.

Christian Dietz (C)

Department of Computer and Information Science, University of Konstanz, 78457, Konstanz, Germany.
KNIME GmbH, 78467, Konstanz, Germany.

Timo Trefzer (T)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany.
Digital Health Center, Berlin Institute of Health (BIH), Charité-Universitätsmedizin, 10117, Berlin, Germany.

Johannes Meisig (J)

Institute of Pathology, Charité-Universitätsmedizin, 10117, Berlin, Germany.

Christoph van Thriel (C)

Leibniz Research Centre for Working Environment and Human Factors (IfADo), Technical University of Dortmund, 44139, Dortmund, Germany.

Margit Henry (M)

Center of Physiology and Pathophysiology, Institute of Neurophysiology, University of Cologne (UKK), 50931, Cologne, Germany.

Michael R Berthold (MR)

Department of Computer and Information Science, University of Konstanz, 78457, Konstanz, Germany.

Nils Blüthgen (N)

Institute of Pathology, Charité-Universitätsmedizin, 10117, Berlin, Germany.

Agapios Sachinidis (A)

Center of Physiology and Pathophysiology, Institute of Neurophysiology, University of Cologne (UKK), 50931, Cologne, Germany.

Jörg Rahnenführer (J)

Department of Statistics, TU Dortmund, 44221, Dortmund, Germany.

Jan G Hengstler (JG)

Leibniz Research Centre for Working Environment and Human Factors (IfADo), Technical University of Dortmund, 44139, Dortmund, Germany.

Tanja Waldmann (T)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany.

Marcel Leist (M)

In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Chair Foundation, University of Konstanz, Box 657, 78457, Konstanz, Germany. Marcel.leist@uni-konstanz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Différenciation cellulaire › Development of a neural rosette formation...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Development of a neural rosette formation...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Development of a neural rosette formation...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches neurales › Development of a neural rosette formation...
questionsmedicales.fr › Troubles mentaux › Troubles du développement neurologique › Development of a neural rosette formation...
questionsmedicales.fr › Actions chimiques et utilisations › Actions toxiques › Noxas › Neurotoxines › Development of a neural rosette formation...
questionsmedicales.fr › Techniques d'investigation › Techniques de sonde moléculaire › Séquençage par oligonucléotides en batterie › Development of a neural rosette formation...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Test des rosettes › Development of a neural rosette formation...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Development of a neural rosette formation...
questionsmedicales.fr › Techniques d'investigation › Tests de toxicité › Development of a neural rosette formation...